ANAPRINT SIGNED
Additive Printing for Cell-Based Analysis
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0ANAPRINT project word cloud
Explore the words cloud of the ANAPRINT project. It provides you a very rough idea of what is the project "ANAPRINT" about.
Project "ANAPRINT" data sheet
The following table provides information about the project.
| Coordinator |
AvantiCell Science Ltd
Organization address contact info |
| Coordinator Country | United Kingdom [UK] |
| Project website | http://www.avanticell.com/technologies/projects/anaprint |
| Total cost | 1˙803˙657 € |
| EC max contribution | 1˙262˙560 € (70%) |
| Programme |
1. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument) 2. H2020-EU.2.1.2. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Nanotechnologies) |
| Code Call | H2020-SMEINST-2-2015 |
| Funding Scheme | SME-2 |
| Starting year | 2015 |
| Duration (year-month-day) | from 2015-11-01 to 2018-10-31 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | AvantiCell Science Ltd | UK (AYR) | coordinator | 1˙262˙560.00 |
Map
Project objective
The Project shall develop a unique manufacturing solution for the automated production of complex cell models widely used by industry to test biological activity and biosafety. No means of scalable manufacture presently exists. The technical solution is to assemble cell models by additive manufacturing; to control the resident cells’ locations within these 3D models; to supply the models to customers as pre-assembled, frozen products. The result shall be an analytical tool which, unlike current practice, does not compromise analytical output for convenience, but combines high predictive value and low cost with exceptional user-friendliness. The solution is unique, proprietary and highly positive-disruptive in its industrial sector. Its achievement will be measurable in this Project as an exemplifying, printed hepatotoxicity assay with wide application in drug discovery and biosafety testing. An SME Instrument Phase 1 Project advanced the core printing technology delivering this solution to TRL7, and developed a business plan for its exploitation. That business plan confirmed the wide, cross-industry application of cell-based analysis, from preclinical drug discovery through natural products/food to medical devices and nanosafety, and mapped the advantages of additively-manufactured products onto demonstrable industry trends and customer needs. The business plan and its underpinning technology are founded in the applicant’s long-term strategic goals, evidenced by profitable business in the target market from proprietary cell-based services, and by ancillary technology developments, also to TRL7 and supported by UK national funding, which create unique competitive advantage. The outcome of this Phase 2 Project will be a mature cell-based manufacturing technology, its demonstrable application in a commercial environment, and the assembly of a corporate infrastructure ready to take the Project’s manufacturing solution into a well-scoped and lucrative marketplace.
Deliverables
| Documents Defining Technical Performance | Documents, reports | 2019-04-09 14:22:00 |
Take a look to the deliverables list in detail: detailed list of ANAPRINT deliverables.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ANAPRINT" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "ANAPRINT" are provided by the European Opendata Portal: CORDIS opendata.